Newly Granted European Patent Protects VBL Therapeutics’ Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036 – BioSpace

Newly Granted European Patent Protects VBL Therapeutics’ Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036  BioSpace